Forte Biosciences
Most recent annual filing: 2026-03-15
- FB102 Ph2 topline2H 2026FB102 Ph2 topline, 2H 2026, thesis-defining
- FB102 Ph1 topline2H 2026FB102 Ph1 topline, 2H 2026, material
- Merger FDA decision3Q 2026Merger FDA decision, 3Q 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
Biotech Distilled coverage (5)
- 2026-07-28 UPDATE: Forte Biosciences (FBRX) - argenx Paid $77 a Share
- 2026-07-09 UPDATE: Forte Biosciences (FBRX) - The Canary Sang 🔒 Paid
- 2026-05-12 UPDATE: Forte Biosciences (FBRX) - Fast Track in Celiac, Vitiligo Readout “Shortly” 🔒 Paid
- 2026-04-27 UPDATE: Forte Biosciences (FBRX) - The Dilution Gap Just Closed (And argenx Showed Up) 🔒 Paid
- 2026-04-03 Forte Biosciences (FBRX) - Scientific Deep Dive for FB102 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.